title: Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma.
abstract: Six patients with asthma (American Thoracic Society (ATS) criteria), maintained on inhaled beta 2-agonists alone, were treated with inhaled corticosteroid (budesonide 400 micrograms b.d.) for a period of three months. Prior to steroid therapy, baseline spirometry, bronchodilator response and bronchial hyperresponsiveness were documented and endobronchial biopsies were obtained for immunopathological analysis. Frozen sections of the biopsies were investigated using immunoperoxidase methods, with a panel of monoclonal antibodies selected to reveal the presence and distribution of lymphocyte and macrophage subsets and HLA-DR expression. After three months the studies were repeated. Studies before steroid therapy revealed a T-cell-dominated inflammation in the bronchial wall of all subjects. Baseline airway obstruction, median (range) forced expiratory volume in one second (FEV1) 78.5 (61-109)% of predicted, with a significant bronchodilator response 20.8 (14-33)% and bronchial hyperresponsiveness to histamine geometric mean (SD) PC20FEV1 0.69 (2.5) mg was documented. Steroid therapy caused a significant reduction in bronchial hyperresponsiveness to histamine, with an increase in geometric mean PC20FEV1 to 2.22 (3.2) mg post steroid (p less than 0.03). Concurrent with a reduction in bronchodilator response and an increase in spirometric variables (improved forced midexpiratory flow (FEF25-75) p less than 0.03), there were marked reductions observed in the overall numbers of T-lymphocytes (CD 2, 5, 8), the numbers of CD45RO+ T-cells, and the numbers of macrophages (RFD1+) with the phenotype of antigen presenting cells. In all six subjects, reductions in the quantitative expression of HLA-DR molecules were also seen.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Dept of Respiratory Medicine, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.
authors.forename: C
authors.initials: C
authors.lastname: Burke
authors.forename: C K
authors.initials: CK
authors.lastname: Power
authors.forename: A
authors.initials: A
authors.lastname: Norris
authors.forename: A
authors.initials: A
authors.lastname: Condez
authors.forename: B
authors.initials: B
authors.lastname: Schmekel
authors.forename: L W
authors.initials: LW
authors.lastname: Poulter
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D001706:Biopsy; D001980:Bronchi / Q000276:immunology / Q000473:pathology; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001999:Bronchoscopy; D019819:Budesonide; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D010586:Phagocytes; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D012123:Pulmonary Ventilation; D013147:Spirometry; D013601:T-Lymphocytes
chemical_list: D001993:Bronchodilator Agents; D006684:HLA-DR Antigens; D011282:Pregnenediones; D019819:Budesonide